RecruitingRecruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946 · LTZ Therapeutics, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
About this study
LTZ-301 is a bispecific antibody which is a Myeloid cell engager, which targets B-cells via CD79B, and triggers phagocytosis
Eligibility criteria
Inclusion Criteria:
* Age ≥ 18 years
* Relapsed or refractory to at least 2 prior systemic treatment regimens
* At least 1 bi-dimensionally measurable lesion (≥ 1.5 cm) in longest dimension
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Adequate bone marrow, cardiac, pulmonary, renal, and hepatic function
Exclusion Criteria:
* CLL, or Richters transformation
* Prior solid organ transplant
* Prior allogeneic stem cell transplant
* ASCT within 100 days prior to the first LTZ-301 administration
* Prior CAR-T within 60 days prior to the first LTZ-301 administration
* Current central nervous system (CNS) lymphoma
* Known history of human immunodeficiency virus (HIV) seropositivity
* Active autoimmune disease
* History of clinically significant cardiovascular disease
* symptomatic deep vein thrombosis (DVT) within 3 months of enrollment
* History of other malignancy within 3 years prior to screening
Study design
Enrollment target: 42 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-01-29
Estimated completion: 2028-02
Last updated: 2026-07-24
Interventions
Biological: LTZ-301Biological: LTZ-301Biological: LTZ-301
Primary outcomes
- • Safety and Tolerability (Up to 54 weeks)
Sponsor
LTZ Therapeutics, Inc. · industry
Contacts & investigators
ContactSherry Unabia · contact · sherry.unabia@ltztherapeutics.com · 669-207-0084
All locations (6)
City of HopeRecruiting
Duarte, California, United States
Washington University School of MedicineRecruiting
St Louis, Missouri, United States
Roswell Park Cancer InstituteRecruiting
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center - BergenRecruiting
New York, New York, United States
Tennessee OncologyRecruiting
Nashville, Tennessee, United States
Fred Hutchinson Cancer CenterRecruiting
Seattle, Washington, United States